We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Calprotectin Independently Predicts Relapse in Treated RA

By LabMedica International staff writers
Posted on 14 Jan 2019
Calprotectin is a biomarker of disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) and predicts relapse in juvenile idiopathic arthritis. More...
Higher drug trough serum levels are associated with a good response in patients treated with tumor necrosis factor inhibitors (TNFi).

Biological therapies have dramatically improved the management and prognosis of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Remission or low disease activity is possible in an increasing number of patients. Nevertheless, persistent remission is more difficult to achieve since disease relapses are common.

Scientists from the University of Barcelona (Barcelona, Spain) carried out a longitudinal, prospective, one-year single-center study of 103 patients (47 RA, 56 PsA) receiving TNFi in remission or with low disease activity. All patients underwent clinical assessment at baseline and at 4, 8, and 12 months, including 28-joint swollen and tender joint counts (28-SJC and 28-TJC, respectively), physician and patient global assessment with visual analogue scales (0–100 mm), erythrocyte sedimentation rate (ESR; mm), and C-reactive protein (CRP; mg/dL).

Calprotectin serum levels, TNFi trough serum levels, and antidrug antibodies were determined at baseline (visit 0) and during disease relapse using an enzyme-linked immunosorbent assay (ELISA) test kit Calprolab, calprotectin ELISA (ALP), and Promonitor, respectively. To reduce variations in calprotectin determinations, the whole procedure was performed in a Triturus autoanalyzer. Additionally, serum samples were collected at 4, 8, and 12 months of follow-up to assess longitudinal changes in drug trough serum levels.

The scientists reported that 95 patients completed one year of follow-up, of whom 12 experienced a relapse. At baseline, relapsers had higher calprotectin levels, lower TNFi TSL, and higher power Doppler (PD) activity than nonrelapsers. Receiver operating characteristic (ROC) analysis showed calprotectin fully predicted relapse (area under the curve (AUC) = 1.00). The cut-off levels determined by ROC analysis for the optimal prediction of relapse for calprotectin, TNFi serum levels, and PD score were 3.7 μg/mL, 1.61 μg/mL, and 4, respectively.

The authors concluded that time-to-remission/low disease activity, calprotectin serum levels, TNFi TSL, and PD score were significantly associated with disease relapse. However, only baseline calprotectin serum levels independently predicted disease relapse in RA and PsA patients under TNFi therapy. The study was published on December 13, 2018 in the journal Arthritis Research and Therapy.

Related Links:
University of Barcelona


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining Management Software
DakoLink
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.